HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chen, J. Articles by Quinn, T. P. Search for Related Content PubMed PubMed Citation Articles by Chen, J. Articles by Quinn, T. P.

Evaluation of an ¹¹¹In-DOTA–Rhenium Cyclized -MSH Analog: A Novel Cyclic-Peptide Analog with Improved Tumor-Targeting Properties

Departments of Biochemistry, Radiology, and Chemistry, University of Missouri–Columbia, Columbia; and Harry S. Truman Memorial Veterans Hospital, Columbia, Missouri

View larger version (14K): [in a new window]   FIGURE 1. Structure of DOTA-ReCCMSH.

View larger version (36K): [in a new window]   FIGURE 2. Radioactivity uptake (%ID) in urine (A), intestines (B), and kidneys (C) for 111In-DOTA–ReCCMSH (ReCCMSH), DOTA-CCMSH (CCMSH), DOTA-CMSH (CMSH), and DOTA-NDP (NDP) in B16/F1 murine melanoma–bearing C57 mice at 0.5, 2, 4, and 24 h after injection (n = 5).

View larger version (20K): [in a new window]   FIGURE 3. Tumor retention of radioactivity and clearance of radioactivity from normal tissues for 111In-DOTA–ReCCMSH over time (%ID/g) (n = 5). Area under curve (AUC) and ratio of tumor AUC to tissue AUC for blood, lung, liver, and carcass are also listed.